Nanopublication: RA9vVSvpMh

Full identifier: http://purl.org/np/RA9vVSvpMh_mhL8rWovmIfyol2wohIzsGDoDkDRfy5hE0

Raw formats: TriG(html,txt), JSON-LD(txt), N-Quads(txt), XML(txt)

Checking for updates...

 RA9vVSvpMh comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RA9vVSvpMh...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "omeprazole delayed release capsules are a proton pump inhibitor ppi indicated for the treatment of active duodenal ulcer in adults 1 1 eradication of helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults 1 2 treatment of active benign gastric ulcer in adults 1 3 treatment of symptomatic gastroesophageal reflux disease gerd in patients 2 years of age and older 1 4 maintenance of healing of ee due to acid mediated gerd in patients 2 years of age and older 1 6 pathologic hypersecretory conditions in adults 1 7 omeprazole delayed release capsules are a proton pump inhibitor ppi indicated for the treatment of active duodenal ulcer in adults 1 1 eradication of helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults 1 2 treatment of active benign gastric ulcer in adults 1 3 treatment of symptomatic gastroesophageal reflux disease gerd in patients 2 years of age and older 1 4 maintenance of healing of ee due to acid mediated gerd in patients 2 years of age and older 1 6 pathologic hypersecretory conditions in adults 1 7 omeprazole delayed release capsules are indicated for short term treatment of active duodenal ulcer in adults most patients heal within four weeks some patients may require an additional four weeks of therapy eradication of h pylori has been shown to reduce the risk of duodenal ulcer recurrence triple therapy omeprazole delayed release capsules in combination with clarithromycin and amoxicillin is indicated for treatment of patients with h pylori infection and duodenal ulcer disease active or up to 1 year history to eradicate h pylori in adults dual therapy omeprazole delayed release capsules in combination with clarithromycin are indicated for treatment of patients with h pylori infection and duodenal ulcer disease to eradicate h pylori in adults among patients who fail therapy omeprazole delayed release capsules with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy in patients who fail therapy susceptibility testing should be done if resistance to clarithromycin is demonstrated or susceptibility testing is not possible alternative antimicrobial therapy should be instituted see clinical pharmacology 12 4 and the clarithromycin prescribing information microbiology sectio n omeprazole delayed release capsules are indicated for short term treatment 4 to 8 weeks of active benign gastric ulcer in adults omeprazole delayed release capsules are indicated for the treatment of heartburn and other symptoms associated with gerd for up to 4 weeks in patients 2 years of age and older pediatric patients 2 years of age to adults omeprazole delayed release capsules are indicated for the short term treatment 4 to 8 weeks of ee due to acid mediated gerd that has been diagnosed by endoscopy in patients 2 years of age and older the efficacy of omeprazole delayed release capsules used for longer than 8 weeks in patients with ee has not been established if a patient does not respond to 8 weeks of treatment an additional 4 weeks of treatment may be given if there is recurrence of ee or gerd symptoms e g heartburn additional 4 to 8 week courses of omeprazole delayed release capsules may be considered omeprazole delayed release capsules are indicated for the maintenance healing of ee due to acid mediated gerd in patients 2 years of age and older controlled studies do not extend beyond 12 months omeprazole delayed release capsules are indicated for the long term treatment of pathological hypersecretory conditions e g zollinger ellison syndrome multiple endocrine adenomas and systemic mastocytosis in adults" .
This is the identifier for this whole nanopublication. http://purl.org/np/RA9vVSvpMh... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-06-30T08:55:16.351+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RA9vVSvpMh... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RA9vVSvpMh... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RA9vVSvpMh... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RA9vVSvpMh...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RA9vVSvpMh... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RA9vVSvpMh...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 30 Jun 2021, 06:55:16 UTC

show references